- Current COO, David Millette, assumes new role of co-CEO
- Founder and CSO, Dr. Guy Sauvageau, now co-CEO with Mr. Millette
- Co-CEOs to have clearly delineated roles and responsibilities with joint leadership over strategy and direction
MONTREAL, November 9, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that its Board of Directors has approved the implementation of a new co-Chief Executive Officer (co-CEO) management structure with the appointment of David Millette to serve as co-CEO alongside Dr. Guy Sauvageau, Founder and Chief Scientific Officer (CSO) of ExCellThera. Mr. Millette has also been elected to the Board of Directors.
In their respective roles as co-CEOs, Guy Sauvageau, who continues as CSO, will implement ExCellThera’s mission and vision and be responsible for R&D, technology, clinical strategy, KOL engagement and culture. David Millette, who continues as COO, will be responsible for leading and implementing the company’s commercial strategy, business development, financing activities and operations. As co-CEOs, Dr. Sauvageau and Mr. Millette will be jointly responsible for leading the overall strategy and direction of ExCellThera and each will report directly to the Board of Directors.
Prior to this appointment, Mr. Millette served as ExCellThera’s Chief Financial Officer (CFO) since joining the company in April 2018, and he has also served as the company’s Chief Operating Officer (COO) since June 2019.
Michael May, Chairman of ExCellThera’s Board of Directors commented on the appointment: “David has consistently demonstrated outstanding organizational leadership skills together with deep corporate experience and operational expertise. Given ExCellThera’s continued corporate, clinical, operational and financial progress, the Board determined that the time had come to promote David into a role that will allow him to fully leverage his particular skill-set and expertise alongside Dr. Sauvageau in a manner designed to benefit ExCellThera and its stakeholders. We are also extremely pleased to welcome David to our Board of Directors.”
“David has been my trusted partner in running ExCellThera for the past four years and he has been instrumental to our success to date as a company. I am thrilled to welcome him as co-CEO,” said Dr. Guy Sauvageau. “David has outstanding corporate leadership experience and operational expertise, and I could not be happier for his well-deserved promotion that formalizes and reflects how we already operate and manage ExCellThera.”
“ExCellThera’s success to date is a testament to Guy’s visionary leadership and his personal unwavering commitment to improving patients’ lives, built on an impressive culture of innovation, excellence and integrity, as well as a relentless focus on patient well-being and improved clinical outcomes,” said David Millette. “I am honored to serve as co-CEO alongside Guy as we lead ExCellThera into its next phase of progress and development.”
ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its cell expansion and engineering platform, as well as supporting best-in-class clinical trials. excellthera.com